Drug
THP
THP is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
recruiting133%
not_yet_recruiting267%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable
A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer
NCT07844291
recruitingphase_2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294508
not_yet_recruitingphase_2
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
NCT06548178
Clinical Trials (3)
Showing 3 of 3 trials
NCT07844291Not Applicable
A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer
NCT07294508Phase 2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06548178Phase 2
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3